Efgartigimod in Myasthenia Gravis: Phase 3 Trial Design

被引：0
|
作者：
Howard, J. F., Jr. [1 ]
De Haard, H. [2 ]
Parys, W. [2 ]
Ulrichts, P. [2 ]
Guglietta, A. [2 ]
Mantegazza, R. E.
机构：
[1] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27515 USA
[2] Argenx BVBA, R&D, Ghent, Belgium
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR2151
引用
收藏
页码：353 / 353
页数：1
相关论文
共 50 条
  • [1] ADAPT: A PHASE 3 STUDY OF FCRN ANTAGONIST, EFGARTIGIMOD, IN MYASTHENIA GRAVIS
    Howard, James
    Tuan Vu
    Bril, Vera
    De Bleecker, Jan
    Verschuuren, Jan
    Mantegazza, Renato
    Meisel, Andreas
    Peric, Stojan
    de Haard, Hans
    Parys, Wim
    Guglietta, Antonio
    Ulrichts, Peter
    Murai, Hiroyuki
    MUSCLE & NERVE, 2020, 62 : S76 - S76
  • [2] Ravulizumab and Efgartigimod in Myasthenia Gravis
    Stascheit, Frauke
    Sousa, Carla Daiane Ferreira de
    Aigner, Annette
    Behrens, Malina
    Keller, Christian W.
    Klotz, Luisa
    Lehnerer, Sophie
    Stein, Maike
    Herdick, Meret
    Doksani, Paolo
    Gerischer, Lea M.
    Hoffmann, Sarah
    Lazaridis, Konstantinos
    Tzartos, John
    Wiendl, Heinz
    Meisel, Andreas
    Luenemann, Jan D.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2025, 12 (01):
  • [3] EFGARTIGIMOD IN MYASTHENIA GRAVIS: UPDATE ON CLINICAL DEVELOPMENT AND PHASE 3 ADAPT STUDY
    Ulrichts, Peter
    Guglietta, Antonio
    Beauchamp, Jon
    de Haard, Hans
    Parys, Wim
    MUSCLE & NERVE, 2019, 60 : S133 - S133
  • [4] EFGARTIGIMOD IN MYASTHENIA GRAVIS: UPDATE ON CLINICAL DEVELOPMENT AND PHASE 3 ADAPT STUDY
    Ulrichts, P.
    Guglietta, A.
    Beauchamp, J.
    de Haard, H.
    Parys, W.
    MUSCLE & NERVE, 2019, 60 : S7 - S7
  • [5] TREATMENT OF PATIENTS WITH MYASTHENIA GRAVIS WITH EFGARTIGIMOD: RESULTS OF THE PHASE 3 ADAPT STUDY
    Howard, J.
    Vu, T.
    Bril, V.
    Peric, S.
    Verschuuren, J.
    Mantegazza, R.
    Murai, H.
    Ulrichts, P.
    Guglietta, A.
    de Haard, H.
    Parys, W.
    Beydoun, S.
    Pasnoor, M.
    Karam, C.
    Muppidi, Sr
    Bertorini, T.
    Bhavaraju-Sanka, R.
    Li, Y.
    MUSCLE & NERVE, 2020, 62 : S125 - S126
  • [6] Additional Analyses of the Phase 2 Efgartigimod Study in Myasthenia Gravis
    Howard, James
    Bril, Vera
    Mantegazza, Renato
    Beydoun, Said
    De Rivera Garrido, Fancisco Javier
    Piehl, Fredrik
    Rottoli, Maria Rosa
    Van Damme, Philip
    Vu, Tuan
    Ulrichts, Peter
    Guglietta, Antonio
    Beauchamp, Jon
    de Haard, Hans
    Verschuuren, Jan
    NEUROLOGY, 2020, 94 (15)
  • [7] STUDY DESIGN OF INTRAVENOUS EFGARTIGIMOD IN JUVENILE GENERALIZED MYASTHENIA GRAVIS
    Kuntz, Nancy
    Schwaede, Abigail
    Bogatyreva, Anna
    Podhorna, Jana
    Steeland, Sophie
    Van Bragt, Tonke
    Van Hoorick, Benjamin
    Guglietta, Antonio
    Howard, James
    MUSCLE & NERVE, 2022, 66 : S111 - S111
  • [8] STUDY DESIGN OF INTRAVENOUS EFGARTIGIMOD IN JUVENILE GENERALIZED MYASTHENIA GRAVIS
    Kuntz, Nancy L.
    Bogatyreva, Anna
    Podhorna, Jana
    Steeland, Sophie
    Van Bragt, Tonke
    Van Hoorick, Benjamin
    Guglietta, Antonio
    Howard, James F., Jr.
    MUSCLE & NERVE, 2022, 65 : S12 - S13
  • [9] Efgartigimod: A Review in Generalised Myasthenia Gravis
    Blair, Hannah A.
    DRUGS, 2024, 84 (11) : 1463 - 1474
  • [10] Efgartigimod in refractory autoimmune myasthenia gravis
    Remijn-Nelissen, Linda
    Tannemaat, Martijn R.
    Ruiter, Annabel M.
    Campman, Yvonne J. M.
    Verschuuren, Jan J. G. M.
    MUSCLE & NERVE, 2024, 70 (03) : 325 - 332
12345